Bristlecone Advisors LLC Sells 351 Shares of Zoetis Inc. (NYSE:ZTS)

Bristlecone Advisors LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 2.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 16,117 shares of the company’s stock after selling 351 shares during the period. Bristlecone Advisors LLC’s holdings in Zoetis were worth $2,626,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ZTS. Soltis Investment Advisors LLC bought a new position in shares of Zoetis during the fourth quarter valued at approximately $343,000. Quilter Plc boosted its stake in Zoetis by 17.9% during the fourth quarter. Quilter Plc now owns 353,674 shares of the company’s stock worth $57,624,000 after acquiring an additional 53,596 shares in the last quarter. Wingate Wealth Advisors Inc. purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $63,000. Savant Capital LLC increased its position in Zoetis by 5.3% during the 4th quarter. Savant Capital LLC now owns 6,271 shares of the company’s stock valued at $1,022,000 after buying an additional 313 shares in the last quarter. Finally, Kestra Private Wealth Services LLC raised its stake in Zoetis by 6.5% during the fourth quarter. Kestra Private Wealth Services LLC now owns 82,692 shares of the company’s stock valued at $13,473,000 after buying an additional 5,027 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $171.37 on Monday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $77.32 billion, a price-to-earnings ratio of 32.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The firm has a 50 day moving average of $169.26 and a 200 day moving average of $179.22. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is presently 37.59%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ZTS shares. Morgan Stanley reduced their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.